Full Review
One of the defining advantages of Direct Primary Care is the ability to spend more time with patients and deliver a more personalized experience. Point-of-care testing amplifies that advantage by adding diagnostic immediacy to the equation, transforming visits for acute complaints from "we will send this out and call you tomorrow" into "here are your results, and here is what we are going to do about it." The clinical and experiential impact of this shift is substantial, and after six months of running Abbott's ID NOW and i-STAT Alinity in a DPC practice, we can confidently say these devices earn their place in the budget.
Abbott ID NOW: Rapid Infectious Disease Testing
The ID NOW platform uses isothermal nucleic acid amplification technology to deliver molecular-quality results for influenza A and B, Strep A, COVID-19, and RSV, all from a simple nasal or throat swab with results available in as few as two minutes for a positive result and thirteen minutes for a confirmed negative. In clinical practice, this means that a patient presenting with acute respiratory symptoms can have a definitive molecular diagnosis before the encounter is over, enabling you to prescribe antiviral therapy (where appropriate) immediately rather than empirically. The device itself is about the size of a small toaster, requires no special installation, and operates on a simple workflow of inserting a test cartridge, adding the sample, and closing the lid. Staff training took approximately two hours in our experience, after which medical assistants ran the tests confidently and independently.
i-STAT Alinity: Your In-Office Lab
The i-STAT Alinity is a more versatile platform that extends your in-office testing capabilities beyond infectious disease and into chemistry, blood gases, cardiac markers, and coagulation. From a single fingerstick or venous blood sample, the device can run a basic metabolic panel, assess electrolytes, measure troponin levels for cardiac complaints, check PT/INR for anticoagulation management, and more. The cartridge-based system is self-calibrating and requires minimal maintenance, though the variety of available cartridges means you will want to carefully select which panels to stock based on your patient population and practice patterns. In our testing practice, the most commonly used panels were the Chem8+ for general metabolic assessment and the CG4+ for patients presenting with dyspnea or chest pain.
The Financial Case
The combined upfront investment of approximately $12,700 for both devices is significant but manageable when viewed as a capital investment rather than an expense. In our test practice, the devices generated roughly $1,200 per month in ancillary revenue from test charges that patients were happy to pay for the convenience of same-visit results. At that rate, the hardware investment was fully recouped within eleven months. The ongoing economics depend on managing consumable costs carefully, maintaining appropriate test pricing, and ensuring that cartridge inventory does not expire before use. Practices with higher acute visit volumes will see faster ROI, while very small practices may want to start with the ID NOW alone and add the i-STAT once patient volume justifies the investment.
EMR Integration
Both devices offer connectivity options for sending results directly to an EMR system, though the smoothness of this integration varies significantly by EMR platform. In our testing, practices using Hero EMR experienced the best integration, with results flowing automatically into the patient chart and triggering the Results Hero interpretation engine. Practices using other EMR systems often needed to enter results manually or use middleware to bridge the connection, which diminishes some of the workflow efficiency that makes POCT compelling in the first place.